Reportstack has announced a new market research publication on Regenerative Medicine and Stem Cells Partnering Terms and Agreements which provides comprehensive understanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in regenerative medicine and stem cells deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for regenerative medicine and stem cells
The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2009 including financial terms where available including over 650 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The report provides an orientation of drug dealmaking and business activities, an introduction to the report, an overview of the trends in regenerative medicine and stem cells dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms, a review of the leading regenerative medicine and stem cells deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
The report also provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of regenerative medicine and stem cells deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. It also provides a comprehensive and detailed review of regenerative medicine and stem cells partnering deals signed and announced since 2009, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in regenerative medicine and stem cells partnering and dealmaking since 2009.
In addition, a comprehensive appendix is provided organized by regenerative medicine and stem cells partnering company A-Z , deal type definitions and regenerative medicine and stem cells partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of regenerative medicine and stem cells technologies and products.
Regenerative Medicine and Stem Cells Partnering Terms and Agreements provides the reader with the following key benefits:
In-depth understanding of regenerative medicine and stem cells deal trends since 2009
Access to headline, upfront, milestone and royalty data
Analysis of the structure of regenerative medicine and stem cells agreements with numerous real life case studies
Comprehensive access to actual regenerative medicine and stem cells contracts entered into by the world’s biopharma companies
Detailed access to actual regenerative medicine and stem cells contracts enter into by the leading fifty big pharma companies
Insight into the terms included in a regenerative medicine and stem cells agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Trends in regenerative medicine and stem cells deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for regenerative medicine and stem cells
The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2009 including financial terms where available including over 650 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The report provides an orientation of drug dealmaking and business activities, an introduction to the report, an overview of the trends in regenerative medicine and stem cells dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms, a review of the leading regenerative medicine and stem cells deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
The report also provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of regenerative medicine and stem cells deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. It also provides a comprehensive and detailed review of regenerative medicine and stem cells partnering deals signed and announced since 2009, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in regenerative medicine and stem cells partnering and dealmaking since 2009.
In addition, a comprehensive appendix is provided organized by regenerative medicine and stem cells partnering company A-Z , deal type definitions and regenerative medicine and stem cells partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of regenerative medicine and stem cells technologies and products.
Regenerative Medicine and Stem Cells Partnering Terms and Agreements provides the reader with the following key benefits:
In-depth understanding of regenerative medicine and stem cells deal trends since 2009
Access to headline, upfront, milestone and royalty data
Analysis of the structure of regenerative medicine and stem cells agreements with numerous real life case studies
Comprehensive access to actual regenerative medicine and stem cells contracts entered into by the world’s biopharma companies
Detailed access to actual regenerative medicine and stem cells contracts enter into by the leading fifty big pharma companies
Insight into the terms included in a regenerative medicine and stem cells agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Companies Mentioned
Abbott
Astellas
AstraZeneca
Bayer
Boehringer Ingelheim
Dainippon Sumitomo
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Merck KGaA
Novartis
Otsuka
Pfizer
Roche
Sanofi
Teva
UCB
Astellas
AstraZeneca
Bayer
Boehringer Ingelheim
Dainippon Sumitomo
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Merck KGaA
Novartis
Otsuka
Pfizer
Roche
Sanofi
Teva
UCB
To view the table of contents and know more details please visit Regenerative Medicine and Stem Cells Partnering Terms and Agreements.
No comments:
Post a Comment